PharmaCyte Biotech Inc (PMCB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.77M
Last updated: Nov 17, 2026 at 4:10 PM ET
PharmaCyte Biotech Inc (PMCB) Statistics
PharmaCyte Biotech (PMCB) has a market cap of $3.77M. It holds $17.74M more cash than debt, 469.98% of its market cap. Its share count is up 57.98% from a year earlier.
Total Valuation
| Market Cap | $3.77M |
|---|---|
| Latest price (Nov 17, 2026) | $5.38 |
Key Dates
The next earnings report is expected on Dec 16, 2026, covering the quarter ending Oct 31, 2026.
| Next Earnings Date | Dec 16, 2026 (expected) |
|---|---|
| Last Earnings Date | Sep 14, 2026 |
| Fiscal Year End | April |
Price Statistics
The stock is down 64.02% over 52 weeks and trades 26.30% below its 50-day average.
| Beta (1Y) | 1.93 |
|---|---|
| 52-Week Change | -64.02% |
| 1-Month Change | -17.21% |
| 3-Month Change | -46.81% |
| 6-Month Change | -61.32% |
| 5-Year Change | -89.29% |
| 10-Year Change | -99.51% |
| Total Return (1Y) | -64.02% |
| Total Return (3Y CAGR) | -48.22% |
| Total Return (5Y CAGR) | -35.79% |
| Return vs SPY (1Y) | -73.96% |
| Max Drawdown (1Y) | -76.79% |
| Max Drawdown (3Y) | -88.76% |
| Sharpe Ratio (1Y) | -1.03 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $7.30 |
| 200-Day Average | $11.64 |
| 52-Week Range | $4.69 to $28.69 |
| RSI (14 Days) | 33.6 |
| Average Volume (20 Days) | 190.68K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 40.30x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 40.30x |
|---|---|
| Quick Ratio | 40.30x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -58.69% over the last 12 months, against a 5-year average of -1.74%.
| Return on Equity (ROE) | -58.69% |
|---|---|
| Return on Assets (ROA) | -43.98% |
| ROE (5Y Average) | -1.74% |
| ROA (5Y Average) | 0.80% |
| ROIC (5Y Average) | -2.11% |
Scores
PMCB has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
| Operating Income | -$7.01M |
|---|---|
| Pretax Income | -$16.15M |
| Net Income | -$16.15M |
| Reported EPS (TTM) | -$37.22 |
Trailing 12 months through Jul 31, 2026.
Balance Sheet
Shareholder equity funds 74.94% of the $36.71M in total assets.
| Cash and Equivalents | $17.74M |
|---|---|
| Total Debt | $0 |
| Net Cash | $17.74M |
| Net Cash Per Share | $31.39 |
| Working Capital | $30.21M |
| Shareholder Equity | $27.51M |
| Book Value Per Share | $48.68 |
| Total Assets | $36.71M |
| Total Liabilities | $6.90M |
Balance sheet as of Jul 31, 2026.
Cash Flow
| Operating Cash Flow | -$3.94M |
|---|---|
| FCF Per Share | -$0.37 |
Trailing 12 months through Jul 31, 2026.
Dividends and Yields
PMCB does not pay a dividend.
| Buyback Yield | 13.21% |
|---|---|
| Shareholder Yield | 13.21% |
Stock Splits
The last split was a 1-for-19 reverse split on Nov 13, 2026.
| Last Split Date | Nov 13, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:19 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PMCB
What is PMCB's market cap?
PharmaCyte Biotech has a market cap of $3.77M.
How many shares of PMCB are outstanding?
PharmaCyte Biotech has 565.03K shares outstanding. The count is up 57.98% from a year earlier.
Does PMCB pay a dividend?
No. PharmaCyte Biotech does not pay a dividend.
How much debt does PMCB have?
PharmaCyte Biotech has $0 of total debt and $17.74M of cash and equivalents, a net cash position of $17.74M.
PMCB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors